Development and application of antibody-drug conjugates in gynecological cancers

Area of Science:

• Oncology
• Pharmacology
• Biochemistry

Background:

• Gynecological cancers remain a significant health concern for women worldwide.
• Current treatments like immunotherapy and targeted therapies face challenges such as limited efficacy, resistance, and side effects.

Purpose of the Study:

• To provide a comprehensive review of antibody-drug conjugates (ADCs) in gynecological cancer treatment.
• To discuss the structural features, mechanisms of action, molecular characteristics, clinical applications, and challenges of approved and developing ADCs.

Main Methods:

• Literature review of approved and investigational antibody-drug conjugates for gynecological cancers.
• Analysis of structural components, pharmacodynamics, and clinical trial data.
• Synthesis of information on efficacy, resistance mechanisms, and adverse events.

Main Results:

• Antibody-drug conjugates (ADCs) have emerged as a key therapeutic strategy, with several agents approved and more in development.
• ADCs demonstrate specific targeting capabilities, enhancing drug delivery to cancer cells while minimizing systemic toxicity.
• Challenges include optimizing target selection, managing resistance, and mitigating side effects.

Conclusions:

• ADCs offer promising therapeutic prospects for improving outcomes in gynecological cancer patients.
• Further research is needed to overcome existing challenges and fully realize the potential of ADCs in this field.
• The review highlights the evolving landscape and future directions for ADC development in gynecological oncology.